Remove tag pharma-sales
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. It should be a warning to other pharma companies. Now Biogen is a shell of a company selling off assets to survive.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs come with a high price tag. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US.

Antibody 262
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The drug made almost $17 million in US sales in the third quarter.

Drugs 87
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.

Branding 106
article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.

Radiology 109
article thumbnail

With rivals threatening, Argenx scores key myasthenia gravis win

pharmaphorum

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).